3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
32
Metastatic Castration-resistant Prostate Cancer
3
Prostatic Diseases
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Urogenital Neoplasms
1
Thrombocytopenia
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Hormone Naive Prostate Cancer
1
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
1
Liver Neoplasms
1
High-Risk Localized Prostate Cancer
1
Glioma
1
Glioblastoma
1
Genital Neoplasms, Male
1
Genital Diseases, Male
1
Disease
1
Cytopenia
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Astrocytoma
1
Anemia
1
Interventions
Radiosurgery
5
Androgen Antagonists
4
enzalutamide
2
Prednisone
2
Docetaxel
2
talazoparib
1
sipuleucel-T
1
rucaparib
1
olaparib
1
gallium 68 PSMA-11
1
darolutamide
1
cabazitaxel
1
apalutamide
1
XRP6258
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Positron Emission Tomography Computed Tomography
1
Pluvicto
1
Lutetium-177
1
Lutetium
1
Lenograstim
1
Hematologic Tests
1
Granulocyte Colony-Stimulating Factor
1
Gonadotropin-Releasing Hormone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Prostate Cancer Metastatic
×
Pluvicto
×
Clear all
NCT06320067
2025-09-26
STAMPEDE2
University College, London
Phase 3
Recruiting
3,360 enrolled